You have 9 free searches left this month | for more free features.

bortezomib

Showing 1 - 25 of 559

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Bortezomib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Bortezomib
  • Salt Lake City, Utah
    Huntsman Cancer Institute/University of Utah
Sep 7, 2023

Rheumatoid Arthritis Trial in Beijing (bortezomib)

Not yet recruiting
  • Rheumatoid Arthritis
  • bortezomib
  • Beijing, China
    Peking Union Medical College Hospital
Apr 6, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • Bortezomib
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Bortezomib, Glomerulonephritis, MN Trial in Shanghai (Bortezomib)

Recruiting
  • Bortezomib
  • +5 more
  • Bortezomib
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Oct 28, 2022

Alvocade® (Bortezomib) Safety and Effectiveness Study

Completed
  • Multiple Myeloma, Refractory
  • Bortezomib
  • (no location specified)
Aug 19, 2023

Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult Trial in Indianapolis

Not yet recruiting
  • Bone Marrow Transplant Complications
  • +4 more
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
May 30, 2023

Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Bortezomib
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Relapsed/Refractory Immune Thrombocytopenia Trial in Seoul (Bortezomib)

Not yet recruiting
  • Relapsed/Refractory Immune Thrombocytopenia
  • Bortezomib
  • Seoul, Korea, Republic of
  • +1 more
Oct 30, 2022

Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)

Recruiting
  • Newly Diagnosed Multiple Myeloma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Dec 29, 2022

Multiple Myeloma Trial in Hackensack (Bortezomib)

Terminated
  • Multiple Myeloma
  • Bortezomib
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
Jun 24, 2022

Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)

Active, not recruiting
  • Plasma Cell Myeloma
  • Bortezomib
  • +3 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 10, 2023

Multiple Myeloma Trial (Iberdomide, Bortezomib, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jul 18, 2022

Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca Trial run by the National Heart, Lung, and Blood Institute

Completed
  • Chronic Myeloid Leukemia (CML)
  • +4 more
  • Bortezomib
  • NK cells
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 31, 2022

Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,

Active, not recruiting
  • Light Chain Deposition Disease
  • Primary Systemic Amyloidosis
  • Denver, Colorado
  • +4 more
Jan 20, 2023

Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,

Recruiting
  • Multiple Myeloma
  • Monoclonal Gammopathy of Renal Significance
  • Basking Ridge, New Jersey
  • +6 more
Oct 16, 2023

Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)

Active, not recruiting
  • Solid Tumor
  • Urethral Cancer
  • Bortezomib
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 22, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Bortezomib
  • +2 more
  • Jacksonville, Florida
  • +1 more
Jan 5, 2023

Multiple Myeloma Trial in Rionero in Vulture (Bortezomib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Rionero in Vulture, Potenza, Italy
    Irccs Crob
Mar 24, 2022

Multiple Myeloma, Auto Stem Cell Transplant Trial in Hackensack (Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Auto Stem Cell Transplant
  • Bortezomib
  • Hackensack, New Jersey
    John Theurer Cancer Center @ Hackensack University Medical Cente
Dec 23, 2022

Multiple Myeloma Trial (pomalidomide, Bortezomib, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jun 20, 2022

Multiple Myeloma, Myeloma Trial in Poitiers (Isatuximab, Lenalidomide, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Myeloma
  • Poitiers, France
    CHU Poitiers
Sep 5, 2022

Amyloidosis; Systemic Trial in Beijing (Daratumumab, Bortezomib, Dexamethasone)

Active, not recruiting
  • Amyloidosis; Systemic
  • Beijing, China
    Peking Union Medical College Hospital
May 9, 2022

Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma
  • Bortezomib
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Antibody-mediated Rejection Trial in Tehran (Bortezomib)

Recruiting
  • Antibody-mediated Rejection
  • Bortezomib
  • Tehran, Iran, Islamic Republic of
    SBMU
Jan 27, 2022